ReviewPharmaceutics2024

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage.

Bushra Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.